A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

NCT05882045 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the medication retatrutide in adults with obesity and cardiovascular disease to see how it affects body weight over time.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 1,946 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-05 · est. completion 2026-05

Where 169 sites · Argentina, Australia, Canada, Hungary, Mexico, Poland, Puerto Rico, Slovakia, Spain, United States

What this study is testing ClinicalTrials.gov NCT05882045 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Cardiovascular Diseases
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05882045 ↗